To include your compound in the COVID-19 Resource Center, submit it here.

Intellia deal expands Regeneron’s reach into CRISPR therapies

Fresh off Sanofi’s sell-off, Regeneron announced an expanded collaboration with gene editing company Intellia that gives the big biotech access to the coveted CRISPR gene editing technology for additional targets and indications, including hemophilia.

The new deal, which is an extension of a 2016 collaboration, gives Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) rights to five new liver targets for in vivo therapies based on the CRISPR-Cas9 technology, bringing the total to 15. Regeneron also gains a non-exclusive

Read the full 741 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE